Pediatric MATCH: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations

Complete Title: APEC1621F, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

Trial Phase: II

Investigator: Navin Pinto

This phase II trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back or do not respond to treatment and have spread to other places in the body. Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Keywords:

Central Nervous System (CNS)
Hematologic Malignancies
Lymphoma
Lymphoproliferative Disorders
Pediatric Cancers, Miscellaneous
Neuroblastoma
Lymphoma, Non-Hodgkin (NHL)
Neuroectodermal Tumors, Primitive (PNET)
Solid Tumors
Neoplasms, Germ Cell and Embryonal
Immunoproliferative Disorders
Neuroectodermal Tumors
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Immune System Diseases
Histiocytoma
Nervous System Diseases
Neuroectodermal Tumors, Primitive, Peripheral

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.